Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
AssigneesUniversity of Rochester, Cornell University
InventorsLuis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that various mutations in segment 1 and segment 2 of the CIV genome, thereby encoding mutant PB2 and PB1 protein, render the virus to be temperature-sensitive.
Claims13
An immunological composition comprising a live-attenuated canine influenza virus (LACIV), wherein the LACIV comprises segment 1 of the viral genome encoding mutant PB2 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and segment 2 of the viral genome encoding mutant PB1 comprising the amino acid sequence of SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.